Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: Comparison with Memantine

Behavioural Brain Research

Volumn 252, Issue , 2013, Pages 415-421

  Hemmati, Fatemeh ^a   Dargahi, Leila ^b   Nasoohi, Sanaz ^b   Omidbakhsh, Rana ^a   Mohamed, Zahurin ^a   Chik, Zamri ^a   Naidu, Murali ^a   Ahmadiani, Abolhassan ^a,b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer's disease; FTY720; Gene profiling; Memantine; Sphingosine 1 phosphate

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CASPASE 3; CHOLINE ACETYLTRANSFERASE; FINGOLIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1BETA; MEMANTINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BDNF GENE; BRAIN NERVE CELL; C JUN N TERMINAL KINASE 1 GENE; CALMODULIN DEPENDENT PROTEIN KINASE II GENE; CASPASE 3 GENE; CELL LOSS; CELL SURVIVAL; CELL VIABILITY; CHOLINE ACETYL TRANSFERASE GENE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFECT; DRUG RESPONSE; EXTRACELLULAR SIGNAL REGULATED KINASE 2 GENE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; INTERLEUKIN 1BETA GENE; IRF 3 GENE; LEARNING DISORDER; MALE; MEMORY DISORDER; NEUROPROTECTION; NFKB GENE; NONHUMAN; OUTCOME ASSESSMENT; P38 MITOGEN ACTIVATED PROTEIN KINASE GENE; PPAR GAMMA GENE; PRIORITY JOURNAL; RAT; TNF ALPHA GENE;

ALZHEIMER'S DISEASE; FTY720; GENE PROFILING; MEMANTINE; SPHINGOSINE-1-PHOSPHATE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AVOIDANCE LEARNING; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MALE; MEMANTINE; MITOGEN-ACTIVATED PROTEIN KINASES; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS; SPHINGOSINE;

EID: 84880150760     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.06.016     Document Type: Article

References (71)

1. Birks J. Cholinesterase inhibitors for Alzheimer's disease (Review). Cochrane Database of Systematic Reviews 2006, 1:CD005593.
2. Olivares D.K., Deshpande V., Shi Y.K., Lahiri D.H., Greig N.T., Rogers J., et al. N-methyl d-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimers disease, vascular dementia and Parkinsons disease. Current Alzheimer Research 2012, 9:746-758.
3. Thomas S.J., Grossberg G.T. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clinical Interventions in Aging 2009, 4:367-377.
4. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, 2:CD003154.
5. Maidment I.D., Fox C.G., Boustani M., Rodriguez J., Brown R.C., Katona C.L. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Annals of Pharmacotherapy 2008, 42:32-38.
6. Salloway S. Current and future treatments for Alzheimer's disease. CNS Spectrums 2013, 1:19-33.
7. He X., Huang Y., Li B., Gong C.-X., Schuchman E.H. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiology of Aging 2010, 31:398-408.
8. Sun G.Y., Shelat P.B., Jensen M.B., He Y., Sun A.Y., Simonyi A. Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular Medicine 2010, 12:133-148.
9. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Reviews Drug Discovery 2010, 9:883-897.
10. Chun J., Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discovery Medicine 2011, 12:213-228.
11. Lahiri S., Park H., Laviad E.L., Lu X., Bittman R., Futerman A.H. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. Journal of Biological Chemistry 2009, 284:16090-16098.
12. Berdyshev E.V., Gorshkova I., Skobeleva A., Bittman R., Lu X., Dudek S.M., et al. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. Journal of Biological Chemistry 2009, 284:5467-5477.
13. Asle-Rousta M., Kolahdooz Z., Oryan S., Ahmadiani A., Dargahi L. FTY720 (Fingolimod) attenuates beta-amyloid peptide (Aβ42)-induced impairment of spatial learning and memory in rats. Journal of Molecular Neuroscience 2013, 4:1-9.
14. Jackson S.J., Giovannoni G., Baker D. Fingolimod modulates microglial activation to augment markers of remyelination. Journal of Neuroinflammation 2011, 8:76.
15. Foster C.A., Mechtcheriakova D., Storch M.K., Balatoni B., Howard L.M., Bornancin F., et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathology 2008, 19:254-266.
16. Zhang F., Kang Z., Li W., Xiao Z., Zhou X. Roles of brain-derived neurotrophic factor/tropomyosin-related kinase B (BDNF/TrkB) signalling in Alzheimer's disease. Journal of Clinical Neuroscience 2012, 19:946-949.
17. Deogracias R., Yazdani M., Dekkers M.P., Guy J., Ionescu M.C.S., Vogt K.E., et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:14230-14235.
18. Gass P., Herdegen T., Bravo R., Kiessling M. Induction and suppression of immediate early genes in specific rat brain regions by the non-competitive N-methyl-d-aspartate receptor antagonist MK-801. Neuroscience 1993, 53:749-758.
19. Sharp F.R., Jasper P., Hall J., Noble L., Sagar S.M. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Annals of Neurology 2004, 30:801-809.
20. Tomitaka S., Hashimoto K., Narita N., Sakamoto A., Minabe Y., Tamura A. Memantine induces heat shock protein HSP70 in the posterior cingulate cortex, retrosplenial cortex and dentate gyrus of rat brain. Brain Research 1996, 740:1-5.
21. Marvanová M., Lakso M., Pirhonen J., Nawa H., Wong G., Castrén E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Molecular and Cellular Neuroscience 2001, 18:247-258.
22. Vukic V., Callaghan D., Walker D., Lue L.-F., Liu Q.Y., Couraud P.-O., et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiology of Disease 2009, 34:95-106.
23. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press.
24. Wise L.E., Lichtman A.H. The uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial-arm maze memory task. European Journal of Pharmacology 2007, 575:98-102.
25. Ge P.-F., Luo T.-F., Zhang J.-Z., Chen D.-W., Luan Y.-X., Fu S.-L. Ischemic preconditioning induces chaperone hsp70 expression and inhibits protein aggregation in the CA1 neurons of rats. Neuroscience Bulletin 2008, 24:288-296.
26. Ching L.K., Mompoint F., Guderian J.A., Picone A., Orme I.M., Coler R.N., et al. Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay. Journal of Immunological Methods 2011, 373:54-62.
27. Pandey A., Mann M. Proteomics to study genes and genomes. Nature 2000, 405:837-846.
28. King D.L., Arendash G.W., Crawford F., Sterk T., Menendez J., Mullan M.J. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behavioural Brain Research 1999, 103:145-162.
29. Schmidt R., Kienbacher E., Benke T., Dal-Bianco P., Delazer M., Ladurner G., et al. Sex differences in Alzheimer's disease. Neuropsychiatry 2008, 22:1-15. [Review].
30. Viña J., Lloret A. Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. Journal of Alzheimer's Disease 2010, 20:S527-S533.
31. Nasiraei-Moghadam S., Sherafat M.A., Safari M.S., Moradi F., Ahmadiani A., Dargahi L. Reversal of prenatal morphine exposure-induced memory deficit in male but not female rats. Journal of Molecular Neuroscience 2013, 50:58-69.
32. Crouch P.J., Harding S.-M.E., White A.R., Camakaris J., Bush A.I., Masters C.L. Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease. International Journal of Biochemistry & Cell Biology 2008, 40:181-198.
33. Di Carlo M. Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways. European Biophysics Journal 2010, 39:877-888.
34. Takasugi N., Sasaki T., Suzuki K., Osawa S., Isshiki H., Hori Y., et al. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. The Journal of Neuroscience 2011, 31:6850-6857.
35. Yi H., Lee S.J., Lee J., Myung C.-S., Park W.-K., Lim H.-J., et al. Sphingosylphosphorylcholine attenuated β-amyloid production by reducing BACE1 expression and catalysis in PC12 cells. Neurochemical Research 2011, 36:2083-2090.
36. Umemura K., Yamashita N., Yu X., Arima K., Asada T., Makifuchi T., et al. Autotaxin expression is enhanced in frontal cortex of Alzheimer-type dementia patients. Neuroscience Letters 2006, 400:97-100.
37. Gomez-Brouchet A., Pchejetski D., Brizuela L., Garcia V., Altié M.-F., Maddelein M.-L., et al. Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-β peptide. Molecular Pharmacology 2007, 72:341-349.
38. Tarassishin L., Suh H.-S., Lee S.C. Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway. Journal of Neuroinflammation 2011, 8:1-18.
39. Ferraro L., Tomasini M.C., Tanganelli S., Mazza R., Coluccia A., Carratù M.R., et al. Developmental exposure to methylmercury elicits early cell death in the cerebral cortex and long-term memory deficits in the rat. International Journal of Developmental Neuroscience 2009, 27:165-174.
40. Karlsson O., Roman E., Berg A.-L., Brittebo E.B. Early hippocampal cell death, and late learning and memory deficits in rats exposed to the environmental toxin BMAA (β-N-methylamino-l-alanine) during the neonatal period. Behavioural Brain Research 2011, 219:310-320.
41. Kuranaga E. Beyond apoptosis: caspase regulatory mechanisms and functions in vivo. Genes Cells 2012, 17:83-97.
42. Mehan S., Meena H., Sharma D., Sankhla R. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. Journal of Molecular Neuroscience 2011, 43:376-390.
43. Nozaki K., Nishimura M., Hashimoto N. Mitogen-activated protein kinases and cerebral ischemia. Molecular Neurobiology 2001, 23:1-19.
44. Um M.Y., Ahn J.Y., Kim M.K., Ha T.Y. Sesaminol glucosides protect β-amyloid induced apoptotic cell death by regulating redox system in SK-N-SH cells. Neurochemical Research 2012, 4:689-699.
45. Seki M., Lipton S.A. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Progress in Brain Research 2008, 173:495-510.
46. Amadoro G., Ciotti M.T., Costanzi M., Cestari V., Calissano P., Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:2892-2897.
47. Jantas D., Szymanska M., Budziszewska B., Lason W. An involvement of BDNF and PI3-K/Akt in the anti-apoptotic effect of memantine on staurosporine-evoked cell death in primary cortical neurons. Apoptosis 2009, 14:900-912.
48. Matsuda S., Minowa A., Suzuki S., Koyasu S. Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. Journal of Immunology 1999, 162:3321-3326.
49. O'Neill L.A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nature Reviews Drug Discovery 2006, 5:549-563.
50. Estrada-Bernal A., Palanichamy K., Chaudhury A.R., Van Brocklyn J.R. Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. Neuro-oncology 2012, 14:405-415.
51. Lee J.E., Kim S.Y., Jeong Y.M., Yun H.Y., Baek K.J., Kwon N.S., et al. The regulatory mechanism of melanogenesis by FTY720, a sphingolipid analogue. Experimental Dermatology 2011, 20:237-241.
52. Ubai T., Azumma H., Kotake Y., Inamoto T., Takahara K., Ito Y., et al. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Research 2007, 27:75-88.
53. Verri M., Pastoris O., Dossena M., Aquilani R., Guerriero F., Cuzzoni G., et al. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. International Journal of Immunopathology & Pharmacology 2012, 25:345-353.
54. Wenk G.L., Parsons C.G., Danysz W. Potential role of N-methyl-d-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behavioral Pharmacology 2006, 17:411-424.
55. Rosi S., Vazdarjanova A., Ramirez-Amaya V., Worley P., Barnes C., Wenk G. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience 2006, 142:1303-1315.
56. Suzuki S., Enosawa S., Kakefuda T., Shinomiya T., Amari M., Naoe S., et al. A novel immunosuppressant, Fty720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation 1. Transplantation 1996, 61:200-205.
57. Cohen J.A., Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Annals of Neurology 2011, 69:759-777.
58. Aktas O., Küry P., Kieseier B., Hartung H.-P. Fingolimod is a potential novel therapy for multiple sclerosis. Nature Reviews Neurology 2010, 6:373-382.
59. Lee K.D., Chow W.N., Sato-Bigbee C., Graf M.R., Graham R.S., Colello R.J., et al. FTY720 reduces inflammation and promotes functional recovery after spinal cord injury. Journal of Neurotrauma 2009, 26:2335-2344.
60. Wei Y., Yemisci M., Kim H.H., Yung L.M., Shin H.K., Hwang S.K., et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Annals of Neurology 2011, 69:119-129.
61. Gao F., Liu Y.-F., Li X.-W., Wang Y., Wei D., Fingolimod J.W. (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Pharmacology Biochemistry & Behavior 2012, 103:187-196.
62. Tarassishin L., Bauman A., Suh H.-S., Lee S.C. Anti-viral and anti-inflammatory mechanisms of the innate immune transcription factor interferon regulatory factor 3: relevance to human CNS diseases. Journal of Neuroinflammation 2011, 8:1-18.
63. Jung D.Y., Lee H., Jung B.-Y., Ock J., Lee M.-S., Lee W.-H., et al. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-β as a decision maker. Journal of Immunology 2005, 174:6467-6476.
64. Araujo D., Lapchak P., Robitaille Y., Gauthier S., Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. Journal of Neurochemistry 2006, 50:1914-1923.
65. Kása P., Rakonczay Z., Gulya K. The cholinergic system in Alzheimer's disease. Progress in Neurobiology 1997, 52:511-535.
66. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., DeKosky S.T. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. Journal of Chemical Neuroanatomy 2003, 26:233-242.
67. Lang U., Mühlbacher M., Hesselink M., Zajaczkowski W., Danysz W., Danker-Hopfe H., et al. No nerve growth factor response to treatment with memantine in adult rats. Journal of Neural Transmission 2004, 111:181-190.
68. Nyakas C., Granic I., Halmy L.G., Banerjee P., Luiten P.G. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine. Behavioural Brain Research 2011, 221:594-603.
69. Sun C.-y., Qi S.-s., Lou X.-f., Sun S.-h., Wang X., Dai K.-y., et al. Changes of learning, memory and levels of CaMKII, CaM mRNA, CREB mRNA in the hippocampus of chronic multiple-stressed rats. Chinese Medical Journal (Beijing, China, Engl. Ed.) 2006, 119:140-147.
70. Li L., Sengupta A., Haque N., Grundke-Iqbal I., Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Letters 2004, 566:261-269.
71. Kaneider N.C., Lindner J., Feistritzer C., Sturn D.H., Mosheimer B.A., Djanani A.M., et al. The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. FASEB Journal 2004, 18:1309-1311.